We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380

News   Feb 22, 2014

 
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380
 
 
 

RELATED ARTICLES

Drugs to Prevent Stroke and Dementia Show Promise in Early Trial

News

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study.

READ MORE

Scientists Crack the Chemical Code of Complex “Anti-tumor Antibiotic”

News

After 20 years of dedicated research, scientists have cracked the chemical code of an incredibly complex "anti-tumor antibiotic" known to be highly effective against cancer cells as well as drug-resistant bacteria, and have reproduced it synthetically in the lab for the first time.

READ MORE

Targeted Therapy Proves Effective Against Aggressive Blood Cancer in Clinical Trial

News

A multi-institutional clinical trial has given good results for a targeted therapy to treat a rare, aggressive blood cancer known as blastic plasmacytoid dendritic-cell neoplasm (BPDCN).

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE